Skip to content
ChickenStockChickenStock
ResearchABCL
Abcellera Biologics logo

Abcellera Biologics (ABCL) stock

NASDAQ

$11.04-0.72%(-0.08)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-24.56x

Net loss — not comparable

P/B

3.40x

P/S

53.09x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 22.2% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

10 SEC filings
  • Booth AndrewChief Financial Officer · Nov 13, 2026Open-market purchase8,600 shares · $97K
    Avg. price $11.33491,400 shares held after
  • Booth AndrewChief Financial Officer · Nov 13, 2026Option exercise50,000 shares · $16K
    Avg. price $0.3216541,400 shares held after
  • Booth AndrewChief Financial Officer · Nov 13, 2026Gift50,000 shares · $0
    Avg. price $0491,400 shares held after
  • Thermopylae Holdings Ltd.10% owner · Nov 13, 2026Gift125,000 shares · $0
    Avg. price $056,069,662 shares held after
  • Thermopylae Holdings Ltd.10% owner · Nov 12, 2026Open-market purchase60,565 shares · $699K
    Avg. price $11.5456,194,662 shares held after
  • Hayden Michael RDirector · Aug 24, 2026Open-market purchase53,613 shares · $570K
    Avg. price $10.641,373,397 shares held after
  • Montalbano John S.Director · Aug 18, 2026Open-market purchase10,000 shares · $110K
    Avg. price $11.03251,000 shares held after
  • Booth AndrewChief Financial Officer · Aug 14, 2026Open-market purchase37,200 shares · $384K
    Avg. price $10.32482,800 shares held after
  • Hayden Michael RDirector · Aug 12, 2026Open-market purchase46,387 shares · $481K
    Avg. price $10.371,319,784 shares held after
  • Hayden Michael RDirector · Aug 11, 2026Gift50,000 shares · $0
    Avg. price $01,273,397 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Abcellera Biologics (ABCL) stock information

NASDAQ

Abcellera Biologics (ABCL) is listed on NASDAQ. Its market capitalization is about $3.6B. On trailing-twelve-month earnings the P/E ratio is -24.56, and the P/B ratio is 3.4. Return on equity is -13.8%. These figures are computed in-house from official filings and are reference information only.

Abcellera Biologics — frequently asked questions

What is the P/E ratio of Abcellera Biologics (ABCL)?
On a trailing-twelve-month basis, ABCL trades at a P/E ratio of -24.56. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Abcellera Biologics?
ABCL has a market capitalization of about $3.6B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.